

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP**

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

1. Name and Address of Reporting Person* <u>BVF PARTNERS L P/IL</u>  _____ (Last) (First) (Middle) <u>ONE SANSOME STREET, 31ST FLOOR</u>  _____ (Street) <u>SAN FRANCISCO CA 94104</u>  _____ (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>NEUROCRINE BIOSCIENCES INC [ NBIX ]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input checked="" type="checkbox"/> Other (specify below) <u>Indirect Beneficial Owner</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>01/20/2009</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	
		6. Individual or Joint/Group Filing (Check Applicable Line)  <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	01/20/2009		P		18,000 <sup>(3)(7)</sup>	A	\$3.0818	5,848,447 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>
Common Stock	01/20/2009		P		12,000 <sup>(4)(7)</sup>	A	\$3.0818	5,860,447 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>
Common Stock	01/20/2009		P		45,000 <sup>(5)(7)</sup>	A	\$3.0818	5,905,447 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>
Common Stock	01/21/2009		P		6,200 <sup>(3)(7)</sup>	A	\$3.0594	5,911,647 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>
Common Stock	01/21/2009		P		4,000 <sup>(4)(7)</sup>	A	\$3.0594	5,915,647 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>
Common Stock	01/21/2009		P		15,000 <sup>(5)(7)</sup>	A	\$3.0594	5,930,647 <sup>(6)</sup>	I	See footnotes <sup>(1)(2)</sup>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date					

1. Name and Address of Reporting Person* <u>BVF PARTNERS L P/IL</u>  _____ (Last) (First) (Middle) <u>ONE SANSOME STREET, 31ST FLOOR</u>  _____ (Street) <u>SAN FRANCISCO CA 94104</u>  _____ (City) (State) (Zip)
--

1. Name and Address of Reporting Person* <u>BIOTECHNOLOGY VALUE FUND L P</u>  _____ (Last) (First) (Middle) <u>900 N. MICHIGAN AVE., SUITE 1100</u>
--

(Street)	CHICAGO	IL	60611
(City)	(State)	(Zip)	

1. Name and Address of Reporting Person\*

[BIOTECHNOLOGY VALUE FUND II LP](#)

(Last)	(First)	(Middle)	
900 N. MICHIGAN AVE., SUITE 1100			
(Street)	CHICAGO	IL	60611
(City)	(State)	(Zip)	

1. Name and Address of Reporting Person\*

[BVF INVESTMENTS LLC](#)

(Last)	(First)	(Middle)	
900 N. MICHIGAN AVE., SUITE 1100			
(Street)	CHICAGO	IL	60611
(City)	(State)	(Zip)	

1. Name and Address of Reporting Person\*

[BVF INC/IL](#)

(Last)	(First)	(Middle)	
ONE SANSOME STREET, 31ST FLOOR			
(Street)	SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)	

**Explanation of Responses:**

- The shares reported in this response are indirectly beneficially owned by BVF Partners L.P., a Delaware limited partnership ("Partners"), the designated filer of this joint filing on Form 4, and by its general partner, BVF Inc., a Delaware corporation ("BVF Inc."), which is also an investment advisor to Partners. Partners is the general partner of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF, L.P.") and Biotechnology Value Fund II, L.P., a Delaware limited partnership ("BVF2, L.P."), both investment limited partnerships. Partners also is the manager of BVF Investments, L.L.C., a Delaware limited liability company ("Investments"). Pursuant to the operating agreement of Investments, Partners is authorized, among other things, to invest the funds of Samana Capital, L.P., the majority member of Investments, in the shares of Common Stock reported in Table I as being beneficially owned by Investments.
- Mark N. Lampert is the sole shareholder and sole director of BVF Inc., and is an officer of BVF Inc. This joint filing on Form 4 shall not be deemed an admission that Mark N. Lampert is, for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise, the beneficial owner of any equity securities covered by this joint filing.
- Shares directly beneficially owned by BVF, L.P.
- Shares directly beneficially owned by BVF2, L.P.
- Shares directly beneficially owned by Investments.
- Total amount of shares indirectly beneficially owned by Partners and BVF Inc.
- Units may represent aggregation of daily trade activity. Details regarding individual execution amounts and prices are available upon request.

**Remarks:**

[BVF Partners L.P., By: BVF Inc., its GP, By: /s/ Mark N. Lampert](#) [01/22/2009](#)

[BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert](#) [01/22/2009](#)

[BIOTECHNOLOGY VALUE FUND II, L.P., By: BVF Partners L.P., its GP, By: BVF Inc., By: /s/ Mark N. Lampert](#) [01/22/2009](#)

[BVF INVESTMENTS, L.L.C., By: BVF Partners L.P., its Manager, By: BVF Inc., By: /s/ Mark N. Lampert](#) [01/22/2009](#)

[BVF INC., By: /s/ Mark N. Lampert](#) [01/22/2009](#)

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**